Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis

• Verfasst von: Pfaar, Oliver [VerfasserIn]
• Verfasst von: Anders, Clemens Frithjof [VerfasserIn]
• Verfasst von: Hörmann, Karl [VerfasserIn]
• Verfasst von: Klimek, Ludger [VerfasserIn]
• Titel: Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis
• Titelzusatz: a randomized double-blind, placebo-controlled trial
• Verf.angabe: O. Pfaar, J. Mullol, C. Anders, K. Hörmann, L. Klimek
• Jahr: 2012
• Umfang: 8 S.
• Fussnoten: DOI fehlerhaft ; Gesehen am 08.08.2018
• Titel Quelle: Enthalten in: Rhinology
• Ort Quelle: Amsterdam : Journal Rhinology, c/o AMC, 1963
• Jahr Quelle: 2012
• Band/Heft Quelle: 50(2012), 1, Seite 37-44
• ISSN Quelle: 1996-8604
• DOI: doi:10.4193/Rhino10.096
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1578390966

Abstract

Summary: Aim: To evaluate the efficacy and safety of a phytotherapeutic nasal spray containing Cyclamen europaeum (CE) in the treatment of acute rhinosinusitis (ARS). Material/Methods: We performed a randomized, double-blind, placebo-controlled trial of CE nasal spray once daily for 15 days in 99 adult patients with moderate-to-severe ARS who also received amoxicillin 500 mg three times daily for the first 8 days. The primary endpoint was the change in mean total symptom scores (TSS) on day 7. Secondary endpoints included individual symptom scores (nasal congestion, mucus secretion, facial pain, impairment of smell) and endoscopic findings on days 7 and 15 and others. Results: No statistically significant difference in TSS was noted for CE versus placebo on day 7. Moreover, the individual scores were not statistically different between the groups for the ITT-population on day 7. However, both a reduction in facial pain (PP) and an improvement in endoscopically-assessed mucosal obstruction (ITT) significantly favoured CE on day 7. The most common adverse events were nasal burning and mild epistaxis, but no severe adverse events were documented. Conclusion: In summary, this is the first randomized controlled trial on phytotherapy in patients with moderate-to-severe ARS demonstrating clinical safety and some encouraging effects of CE which merit to investigate hytotherapeutic products in further large-scale clinical trials.